Pinnaql, a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, a leading provider of analytical sciences, formulation, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. The acquisition marks Pinnaql’s third tuck-in acquisition in the past 10 months.
Founded in 2007, PRG has built long-standing relationships with pharmaceutical clients by delivering specialized support across formulation and manufacturing processes. Its capabilities complement Pinnaql’s existing focus on engineering, regulation, validation, and quality systems, creating a more comprehensive offering for customers at every stage of the product lifecycle. The combined platform now supports clients from laboratory innovation through manufacturing readiness, helping organizations reduce execution risk, avoid compliance setbacks, and bring therapies to market faster.
3 Boomerang Capital is a lower-middle-market healthcare private equity firm currently investing out of its flagship 3 Boomerang Capital I fund, a $376 million investment vehicle.
KEY QUOTES:
“The addition of PRG marks another major step in building Pinnaql into the partner life sciences companies can rely on, from development to commercial readiness. By combining PRG’s scientific development and scale-up expertise with our established strengths in validation, engineering, quality systems, and regulatory compliance, we can now support clients throughout their full spectrum of growth.”
John Duffin, Chief Executive Officer, Pinnaql
“PRG enhances the platform’s technical depth and further positions Pinnaql as a differentiated partner to life sciences organizations.”
Peter Wen, Principal, 3 Boomerang Capital
